Sarepta Therapeutics, Inc.
SRPT
$105.56
-$2.11-1.96%
| Weiss Ratings | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | C | |||
| Rating Factors | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.52 | |||
| Price History | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.30% | |||
| 30-Day Total Return | -9.07% | |||
| 60-Day Total Return | -16.41% | |||
| 90-Day Total Return | -18.73% | |||
| Year to Date Total Return | -14.93% | |||
| 1-Year Total Return | -12.26% | |||
| 2-Year Total Return | -32.33% | |||
| 3-Year Total Return | 31.26% | |||
| 5-Year Total Return | -9.85% | |||
| 52-Week High % Change | -37.85% | |||
| 52-Week Low % Change | 8.21% | |||
| Price | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $173.25 | |||
| 52-Week Low Price | $99.50 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Jun 21, 2024 | |||
| Valuation | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.45B | |||
| Enterprise Value | 10.44B | |||
| Price/Earnings (TTM) | 45.09 | |||
| Earnings Per Share (TTM) | 2.39 | |||
| Earnings Per Share Growth | -138.99% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 6.14 | |||
| Price/Book (Q) | 6.83 | |||
| Enterprise Value/Revenue (TTM) | 5.49 | |||
| Price | $105.56 | |||
| Enterprise Value/EBITDA (TTM) | 40.79 | |||
| Enterprise Value/EBIT | 47.85 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 108.47M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 274 4000 | |||
| Address | 215 First Street Cambridge, MA 02142 | |||
| Website | www.sarepta.com | |||
| Country | United States | |||
| Year Founded | 1980 | |||
| Profitability | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 11.46% | |||
| Profit Margin | 12.36% | |||
| Management Effectiveness | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 3.77% | |||
| Return on Equity | 19.71% | |||
| Income Statement | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.90B | |||
| Total Revenue (TTM) | 1.90B | |||
| Revenue Per Share | $17.53 | |||
| Gross Profit (TTM) | 778.36M | |||
| EBITDA (TTM) | 255.81M | |||
| EBIT (TTM) | 218.08M | |||
| Net Income (TTM) | 235.24M | |||
| Net Income Avl. to Common (TTM) | 235.24M | |||
| Total Revenue Growth (Q YOY) | 65.94% | |||
| Earnings Growth (Q YOY) | 248.37% | |||
| EPS Diluted (TTM) | 2.39 | |||
| EPS Diluted Growth (Q YOY) | 245.20% | |||
| Balance Sheet | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.35B | |||
| Cash Per Share (Q) | $12.49 | |||
| Total Current Assets (Q) | 3.07B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.53B | |||
| Current Ratio (Q) | 4.201 | |||
| Book Value Per Share (Q) | $15.77 | |||
| Total Assets (Q) | 3.96B | |||
| Total Current Liabilities (Q) | 731.68M | |||
| Total Debt (Q) | 1.34B | |||
| Total Liabilities (Q) | 2.44B | |||
| Total Common Equity (Q) | 1.53B | |||
| Cash Flow | SRPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 755.56M | |||
| Cash from Financing (TTM) | 124.81M | |||
| Net Change in Cash (TTM) | 674.58M | |||
| Levered Free Cash Flow (TTM) | -427.64M | |||
| Cash from Operations (TTM) | -205.79M | |||
